A novel antibody fragment targeting HAb18G/CD147 with cytotoxicity and decreased immunogenicity

Cancer Biology and Therapy

Volumn 8, Issue 11, 2009, Pages 1035-1044

  Zhu, Hongbin ^a   Yang, Bin ^a   Yang, Xiangmin ^a   Wang, Li ^a   Xu, Jun ^a   Liao, Chenggong ^a   Feng, Qiang ^a   Tang, Hao ^a   Hu, Ling ^b   Chen, Zhinan ^a   Li, Yu ^a,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese PLA 254 Hospital   (China)

^c NONE   (China)

Author keywords

Antibody; Antibody dependent cell mediated cytotoxicity (ADCC); Complement dependent cytotoxicity (CDC); HAb18G CD147; Hepatocellular carcinoma (HCC); Human anti mouse antibody (HAMA); Humanization; Immunogenicity

Indexed keywords

ANTINEOPLASTIC AGENT; CD147 ANTIGEN; GLYCINE; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HAB18; RECOMBINANT ANTIBODY; RECOMBINANT HAB18 HUMAN SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CELL LINE; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG SPECIFICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IMMUNOGENICITY; LIVER CELL CARCINOMA; NONHUMAN; SERUM; STRUCTURAL HOMOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD147; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; LIVER NEOPLASMS; MICE; MODELS, MOLECULAR;

EID: 68049128067     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.11.8531     Document Type: Article

References (40)

1. 131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006; 65:435-44.
2. Zhang Z, Bian H, Feng Q, Mi L, Mo T, Kuang A, et al. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 2006; 5:318-22.
3. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45:269-76.
4. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006; 5:808-14.
5. Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, et al. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 2007; 16:196-202.
6. Fiorentini S, De Panfilis G, Pasolini G, Bonfanti C, Caruso A. A partially humanized monoclonal antibody to human IFNgamma inhibits cytokine effects both in vitro and in vivo. Scand J Immunol 2002; 55:284-92.
7. Dall'Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H. Antibody humanization by framework shuffling. Methods 2005; 36:43-60.
8. Rader C, Cheresh DA, Barbas CF, 3rd. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci USA 1998; 95:8910-5.
9. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7.
10. Padlan EA. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 1991; 28:489-98.
11. Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, et al. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol Immunol 2006; 43:1243-57.
12. Zhang W, Feng J, Li Y, Guo N, Shen B. Humanization of an anti-human TNFalpha antibody by variable region resurfacing with the aid of molecular modeling. Mol Immunol 2005; 42:1445-51.
13. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234:779-815.
14. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487-99.
15. Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994; 31:169-217.
16. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45.
17. Survey of methods for measuring human anti-mouse antibodies. HAMA Survey Group. Clin Chim Acta 1993; 215:153-63.
18. DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res 2003; 9:4013-21.
19. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87:361-8.
20. Zhang W, Erkan M, Abiatari I, Giese NA, Felix K, Kayed H, et al. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol Ther 2007; 6:218-27.
21. Frodin JE, Lefvert AK, Mellstedt H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 1992; 21:153-65.
22. Thorpe SJ, Turner C, Heath A, Feavers I, Vatn I, Natvig JB, et al. Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol 2003; 57:85-92.
23. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature biotechnology 2005; 23:1126-36.
24. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37.
25. Scheinberg DA, Chapman PB. Therapeutic applications of monoclonal antibodies for human disease. In: Birch JR and Lennox ES, ed. Monoclonal Antibodies: Principles and Applications. New York: Wiley-Liss, Inc 1995.
26. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G. Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 2005; 26:1890-5.
27. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65:622-31.
28. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65:5907-16.
29. Schmidt FR. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 2004; 65:363-72.
30. Xing J, Yang X, Wang Y, Yao X, Chen Z. Construction and secretory expression in E. coli of anti-HAb18G molecule ScFv gene. Chinese J Immunol 2003; 19:479-82.
31. Allcorn LC, Martin AC. SACS-self-maintaining database of antibody crystal structure information. Bioinformatics 2002; 18:175-81.
32. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927-48.
33. S.J. H, J.M. T. "NACCESS", Computer Program, London: Department of Biochemistry and Molecular Biology, University College 1993.
34. Talwar GP, Gupta R, Gupta SK, Malhotra R, Khanna R, Mitra DK, et al. A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells. Prostate 2001; 46:207-13.
35. Tamura M, Milenic DE, Iwahashi M, Padlan E, Schlom J, Kashmiri SV. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 2000; 164:1432-41.
36. Pavlinkova G, Colcher D, Booth BJ, Goel A, Wittel UA, Batra SK. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 singlechain Fvs. Int J Cancer 2001; 94:717-26.
37. Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol Immunol 2003; 40:337-49.
38. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, et al. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol 1997; 17:96-106.
39. Ku XM, Liao CG, Li Y, Yang XM, Yang B, Yao XY, et al. Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma-associated antigen HAb18G/CD147. Scand J Immunol 2007; 65:435-43.
40. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12.